Literature DB >> 21857161

Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.

Jinyong Wang1, Yangang Liu, Li Xuan Tan, Juinn Cherng Lo, Juan Du, Myung-Jeom Ryu, Erik A Ranheim, Jing Zhang.   

Abstract

We previously showed that widespread expression of Nras G12D/G12D from its endogenous locus in mice leads to an acute myeloproliferative disease (MPD) with a complete penetrance, whereas bone marrow-specific expression of Nras G12D/G12D in recipient mice did not result in sustained MPD phenotypes but 100% penetrant acute T-cell lymphoblastic leukemia/lymphoma (TALL). Such a phenotypic switch also is seen in the case of endogenous oncogenic Kras. Two possibilities might account for this observation and they are not necessarily mutually exclusive. First, the MPD phenotypes in primary Nras G12D/G12D mice might be a transient phenomenon attributable to microenvironmental factors that do not necessarily imply the potential for long-term maintenance in a hematopoietic-cell autonomous manner. Second, it is likely that MPD phenotypes are maintained by genetically altered hematopoietic stem cells (HSCs). Nras G12D/G12D signaling might substantially alter HSC behaviors (e.g. induce their proliferative exhaustion) so that these HSCs no longer sustain MPD phenotypes to a lethal stage in recipient mice. Here, we show some preliminary results to support the second hypothesis. Our results suggest that different lineages of hematopoietic cells might have differential requirements of HSC activity and Nras G12D signaling during leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21857161      PMCID: PMC3218596          DOI: 10.4161/cc.10.17.17195

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  5 in total

1.  Inducible gene targeting in mice.

Authors:  R Kühn; F Schwenk; M Aguet; K Rajewsky
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

2.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Zhongde Wang; Li Xuan Tan; Myung-Jeom Ryu; Benjamin Meline; Juan Du; Ken H Young; Erik Ranheim; Qiang Chang; Jing Zhang
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

3.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

4.  Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.

Authors:  Jing Zhang; Jing Wang; Yangang Liu; Harwin Sidik; Ken H Young; Harvey F Lodish; Mark D Fleming
Journal:  Blood       Date:  2008-12-09       Impact factor: 22.113

5.  Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Juan Du; Myung-Jeom Ryu; Philip R Taylor; Mark D Fleming; Ken H Young; Henry Pitot; Jing Zhang
Journal:  Blood       Date:  2010-10-04       Impact factor: 22.113

  5 in total
  11 in total

1.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

2.  Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.

Authors:  Tongjie Wang; Chen Li; Chengxiang Xia; Yong Dong; Dan Yang; Yang Geng; Jizhen Cai; Jing Zhang; Xiangzhong Zhang; Jinyong Wang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

4.  Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Authors:  Jinyong Wang; Guangyao Kong; Yangang Liu; Juan Du; Yuan-I Chang; Sin Ruow Tey; Xinmin Zhang; Erik A Ranheim; Marc K Saba-El-Leil; Sylvain Meloche; Alisa Damnernsawad; Jingfang Zhang; Jing Zhang
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

5.  Nras overexpression results in granulocytosis, T-cell expansion and early lethality in mice.

Authors:  Louise Berkhoudt Lassen; Borja Ballarín-González; Alexander Schmitz; Annette Füchtbauer; Finn Skou Pedersen; Ernst-Martin Füchtbauer
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

6.  Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.

Authors:  Zhi Wen; Adhithi Rajagopalan; Evan D Flietner; Grant Yun; Marta Chesi; Quinlan Furumo; Robert T Burns; Athanasios Papadas; Erik A Ranheim; Adam C Pagenkopf; Zachary T Morrow; Remington Finn; Yun Zhou; Shuyi Li; Xiaona You; Jeffrey Jensen; Mei Yu; Alexander Cicala; James Menting; Constantine S Mitsiades; Natalie S Callander; P Leif Bergsagel; Demin Wang; Fotis Asimakopoulos; Jing Zhang
Journal:  Blood       Date:  2021-01-07       Impact factor: 25.476

7.  Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.

Authors:  Martin M J Kirschner; Mirle Schemionek; Claudia Schubert; Nicolas Chatain; Stephanie Sontag; Susanne Isfort; Nadina Ortiz-Brüchle; Karla Schmitt; Luisa Krüger; Klaus Zerres; Martin Zenke; Tim H Brümmendorf; Steffen Koschmieder
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

8.  Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Authors:  Daniela Bressanin; Camilla Evangelisti; Francesca Ricci; Giovanna Tabellini; Francesca Chiarini; Pier Luigi Tazzari; Fraia Melchionda; Francesca Buontempo; Pasqualepaolo Pagliaro; Andrea Pession; James A McCubrey; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-08

Review 9.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

Review 10.  Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.

Authors:  Thomas Knight; Julie Anne Elizabeth Irving
Journal:  Front Oncol       Date:  2014-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.